Marra Pasquale, Di Stadio Arianna, Colacurcio Vito, Scarpa Alfonso, La Mantia Ignazio, Salzano Francesco Antonio, De Luca Pietro
Department of Medicine, Surgery, and Dentistry, University of Salerno, 84084 Salerno, Italy.
Department GF Ingrassia, University of Catania, 95123 Catania, Italy.
Healthcare (Basel). 2022 Feb 1;10(2):287. doi: 10.3390/healthcare10020287.
Intranasal dexmedetomidine (IN DEX) is a relatively new sedative agent with supporting evidence on its efficacy and safety, which can be used for procedural sedation in children, and could have a major role in auditory brainstem response testing, especially in the case of non-cooperative children. The goal of this systematic review is to assess the role of IN DEX in ABR testing, evaluating the reported protocol, potential, and limits.
We performed a comprehensive search strategy on PubMed, Scopus, and Google Scholar, including studies in English on the pediatric population, without time restrictions.
Six articles, published between 2016 and 2021, were included in the systematic review. Sedation effectiveness was high across the studies, except for one study; 3 μg/kg was the dosing most often used. A comparison group was present in three studies, with oral chloral hydrate as the drug of comparison. Adverse effects were rarely reported.
This systematic review showed how IN DEX can represent an adequate sedative for children undergoing ABR testing; larger and more rigorous trials are warranted in order to recommend its systematic utilization.
鼻内给予右美托咪定（IN DEX）是一种相对较新的镇静剂，有关于其疗效和安全性的支持证据，可用于儿童的程序性镇静，在听觉脑干反应测试中可能发挥重要作用，尤其是在不合作儿童的情况下。本系统评价的目的是评估IN DEX在听觉脑干反应测试中的作用，评估报告的方案、潜力和局限性。
我们在PubMed、Scopus和谷歌学术上进行了全面的检索策略，包括对儿科人群的英文研究，无时间限制。
系统评价纳入了2016年至2021年间发表的6篇文章。除一项研究外，各项研究的镇静效果均较高；最常使用的剂量为3μg/kg。三项研究中有对照组，以口服水合氯醛作为对照药物。不良反应报告很少。
本系统评价表明IN DEX对接受听觉脑干反应测试的儿童是一种合适的镇静剂；需要进行更大规模、更严格的试验，以推荐其系统应用。
